Amgen Inc. $AMGN is Verity & Verity LLC’s 9th Largest Position

Verity & Verity LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,080 shares of the medical research company’s stock after purchasing an additional 923 shares during the quarter. Amgen makes up 2.3% of Verity & Verity LLC’s holdings, making the stock its 9th largest position. Verity & Verity LLC’s holdings in Amgen were worth $27,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new position in shares of Amgen during the 1st quarter worth approximately $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen in the second quarter worth $27,000. CBIZ Investment Advisory Services LLC increased its position in shares of Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after purchasing an additional 85 shares in the last quarter. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen during the second quarter worth $32,000. Finally, Activest Wealth Management lifted its holdings in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 103 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Citigroup boosted their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 24th. Daiwa Capital Markets upped their price objective on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Morgan Stanley decreased their price objective on shares of Amgen from $333.00 to $329.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 5th. Finally, Wells Fargo & Company set a $400.00 target price on shares of Amgen in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $325.62.

Amgen Stock Performance

Shares of AMGN stock opened at $340.45 on Tuesday. The stock has a market cap of $183.32 billion, a PE ratio of 27.78, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The business has a 50-day simple moving average of $302.19 and a 200-day simple moving average of $293.02. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $345.84.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period last year, the company earned $5.58 earnings per share. Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is currently 73.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.